Variant:
rs3892097 at chr22:42524947 in CYP2D6 (VIP)

Alleles (on + chromosomal strand)
C > T
Alternate Names:
CYP2D6*4, CYP2D6:1846G>A, c.353-1G>A, c.506-1G>A, g.2012G>A, g.21915516C>T, g.26572G>A, g.6937G>A, part of CYP2D6*4

Clinical Annotations

To see the clinical annotation for this variant please register or sign in.

Variant Annotations

PharmGKB variant annotations provide information about variant-drug pairs based on individual PubMed publications. Each annotation represents information from a single paper and the goal is to report the information that the author states, not an interpretation of the paper. The PMID for supporting PubMed publications is found in the "Evidence" field.

Information presented, including study size, allele frequencies and statistics is taken directly from the publication. However, if the author does not correct p-values in cases of multiple hypotheses, curators may apply a Bonferroni correction. Curators attempt to report study size based on the actual number of participants used for the calculation of the association statistics, so the number may vary slightly from what is reported in the abstract of the paper. OMB Race Category information is derived from the paper and mapped to standardized categories. Category definitions may be found by clicking on the "OMB Race Category" link.

There are 13 annotations for this variant. Register or sign in to see them.

There are 3 disease-related annotations for this variant. Register or sign in to see them.

VIP Variant in CYP2D6

CYP2D6 1846G>A (also seen as 1934G>A in the literature) is diagnostic for the non-functional CYP2D6*4 haplotype [Article:10634130]. CYP2D6 1846G>A causes a splicing defect that results in a non-functional protein [Articles:2211621, 1978251, 1978565]. This variant is responsible for the majority of the PMs found in Caucasian populations [Article:9241659], and is also found at much lower frequencies in other populations, such as Koreans [Article:9895131].

Note: The CYP2D6 gene is found on the minus chromosomal strand. Please note that for standardization, the PharmGKB presents all allele base pairs on the positive chromosomal strand, therefore the alleles within our variant annotations will differ (in a complementary manner) from those in this VIP summary that are given on the minus strand as reported in the literature.

Key Publications:
Drugs / Other Molecules
Diseases Cystic Fibrosis Depression Hypertension Neoplasms Pain Parkinson Disease Schizophrenia
Phenotype Datasets Hot flashes in tamoxifen patients
Lipid measurements in tamoxifen study
Lipid measurements in tamoxifen study - set 2
Meperidine N-demethylation by human CYP450 isoforms
Metabolism of yohimbine by human CYP450 isoforms
Patient responses to tamoxifen
Pharmacokinetics of Tamoxifen at 4 months
Thyroid binding globulin in tamoxifen patients

Appendix

CYP2D6: 1846G>A

Genomic Variant & GenBank ID: G3465A on M33388
mRNA Variant & GenBank ID: N/A
Protein Variant & GenBank ID: splicing defect
GoldenPath Position: chr22:40854891 on hg 18
DNA Source Containing
*Homozygous Reference*
*Allele(Coriell Lines):*
GM17201
DNA Source Containing
*Heterozygous*
*Reference*
*Allele* (Coriell Lines):
GM17203
DNA Source Containing
*Homozygous Minor*
*Allele(Coriell Lines):*
GM17225
Key Haplotypes: CYP2D6*4

Connected Drugs

Connected Diseases

Publications related to rs3892097 at chr22:42524947: 15

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Associations Between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 Alleles in Relation to Efavirenz and Nevirapine Pharmacokinetics in HIV-Infected Individuals. Therapeutic drug monitoring. 2012. Heil Sandra G, et al. [Article:22354160@PubMed]
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment. Current medical research and opinion. 2010. Stingl Julia Carolin, et al. [Article:20849243@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease. European journal of clinical pharmacology. 2010. Molanaei Hadi, et al. [Article:19940985@PubMed]
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clinical pharmacology and therapeutics. 2009. Rau T, et al. [Article:19037197@PubMed]
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA : the journal of the American Medical Association. 2009. Schroth Werner, et al. [Article:19809024@PubMed]
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast cancer research : BCR. 2007. Wegman Pia, et al. [Article:17244352@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007. Schroth Werner, et al. [Article:18024866@PubMed]
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. Journal of clinical pharmacy and therapeutics. 2006. Shams M E E, et al. [Article:16958828@PubMed]
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005. Goetz Matthew P, et al. [Article:16361630@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics. 1999. Gaedigk A, et al. [Article:10634130@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Mutation analysis of CYP2D6 locus in the Korean population: identification of rare poor metabolizer alleles at the nucleotide level. Molecules and cells. 1998. Ryu S W, et al. [Article:9895131@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics. 1997. Marez D, et al. [Article:9241659@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site. American journal of human genetics. 1990. Hanioka N, et al. [Article:1978565@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature. 1990. Gough A C, et al. [Article:1978251@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. The Journal of biological chemistry. 1990. Kagimoto M, et al. [Article:2211621@PubMed]

Cross-References

UCSC Golden Path:
chr22:42524947
dbSNP:
rs3892097
ALFRED:
SI015494X

Platform Availability

  • Illumina

Common Searches

PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (R24 GM61374).
©2001-2012 PharmGKB.